ArticleCureus2024
The Role of Advanced Magnetic Resonance Imaging Sequences in Multiple Sclerosis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The neurological condition known as multiple sclerosis (MS) is crippling and has a complicated pathogenesis as well as a wide range of clinical symptoms, including fatigue, difficulty walking, numbness or tingling, muscle spasms and spasticity, weakness, vision problems, dizziness and vertigo, bladder and bowel dysfunction, cognitive impairment, and emotional changes. The complete scope of MS pathology cannot be fully captured by conventional magnetic resonance imaging (MRI) sequences, which has led to the investigation of sophisticated MRI methods for better diagnosis and treatment. Objective This study aims to evaluate the clinical relevance of advanced MRI sequences in multiple sclerosis. Methodology A retrospective cohort study was conducted across multiple specialized medical centers renowned for treating neurological disorders, particularly multiple sclerosis, and involved 310 patients with diverse geography seeking treatment throughout 2022. Records were searched to obtain patient information, demographics, and treatment history. Descriptive statistics and t-tests were among the statistical studies that investigated relationships between MRI biomarkers and clinical factors to help with the diagnosis and treatment of MS. A p-value of <0.05 was significant. Results The research group consisted of 310 MS patients, the majority of whom were female (67.42%) and had a mean age of 34.7 years. With hypertension (14.52%) and hyperlipidemia (19.35%) as prevalent comorbidities, the majority of patients (72.26%) were on disease-modifying treatments. The results of advanced MRI showed that lesions with white matter had higher mean diffusivity (1.25 ± 0.15 mm²/s) on DWI, lesions with reduced magnetization transfer ratio (MTR) (0.15 ± 0.03) on MTI, and lesions with reduced fractional anisotropy (FA) (0.40 ± 0.08) on diffusion tensor imaging (DTI). Additionally, the blood oxygen level-dependent (BOLD) signals in cognitive processing regions (0.75 ± 0.10) on functional MRI were different from those with normal-appearing white matter (0.40 ± 0.08). Conclusion Advanced MRI sequences are essential for bettering MS diagnosis, prognosis, and treatment because they link imaging biomarkers to important clinical parameters, which improves patient care and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.